Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation By Treatment Type
6.1.1 Chemotherapy
6.1.1.1 Cisplatin
6.1.1.2 Taxol
6.1.1.3 Navelbine
6.1.1.4 Camptosar
6.1.1.5 Alimta
6.1.1.6 Docetaxel
6.1.1.7 Vinorelbine
6.1.1.8 Irinotecan
6.1.2 Radiotherapy
6.1.2.1 External Beam
6.1.2.2 Internal Beam
6.1.2.3 Systemic
6.1.3 Other Drugs
6.1.3.1 Abraxane
6.1.3.2 Avastin
6.1.3.3 Crizotinib
6.1.3.4 Ceritinib
6.1.3.5 Gefitinib
6.1.3.6 Afatnib
Chapter 7 Market Segmentation By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Germany
7.2.5 Italy
7.2.6 France
7.2.7 Russia
7.2.8 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 South Korea
7.3.6 Australia
7.3.7 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.4 Argentina
7.4.5 Rest of South America
7.4.6 Others
7.5 The Middle East & Africa
7.5.1 Introduction
7.5.2 Middle-East
7.5.3 Africa
7.5.4 Others
Chapter 8 Lung Cancer, By surgery Type
8.1. Thoracotomy
8.1.1 Lobectomy
8.1.2 Sleeve Resection
8.1.3 Segmentectomy
8.1.4 Pneumonectomy
8.2. Minimally Invasive Procedures
8.2.1. Video-Assisted Thoracoscopic Surgery
8.3. Others
Chapter 9 Lung Cancer, By End-User
9.1. Hospitals
9.2. Adult Lung Cancer Surgery centres
Chapter 10 Company Profiles
10.1. Siemens Healthcare
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiative
10.2. Richard Wolf Gmbh
10.3. Olympus Cor
10.4. Neomend Inc.
10.5. Ethicon Endo-Surgery Inc.
10.6. BSD Medical Corp
10.7. Accuray Inc.
10.8. Trokamed Gmbh
10.9. Karl Storz Gmbh & Co. Kg
10.10. Teleflex Inc.
10.11. Scanlan International Inc.
10.12. Intuitive Surgical Inc.
10.13. Dimeda Surgical Instruments
10.14 Ventana
10.15 Roche
10.16 Genentech
10.17 Boehringer
Chapter 11 Competitive Landscape
10.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
10.2 Strategies Adopted By Top Companies
10.3 Market Share Analysis
Chapter 12 Market Estimates and Forecast
12.1.1 Market Estimation and Forecast by Treatment Type 2017-2023 (USD Million)
12.1.2 Market Estimates and Forecast by surgery Type 2017-2023 (USD Million)
12.1.3 Market Estimates and Forecast by End User 2017-2023 (USD Million)
12.1.4 Market Estimates and Forecast by Geography 2017-2023 (USD Million)
12.1.5 Market Estimates and Forecast by Company 2017-2023 (USD Million)
Chapter 13 Market Insights
13.1 Insights of Industry Experts
13.2 Analyst Opinion (Market Understanding)
13.3 Investment Opportunities
Chapter 14 Appendix
14.1 List of Tables
14.2 List of Figures
